Numis Gives Hikma Pharmaceuticals PLC (LON:HIK) GBX 1560.00 Target; BERTRANDT AG GERMANY (BDGXF) Shorts Decreased By 7.25%

Hikma Pharmaceuticals PLC (LON:HIK) Logo

BERTRANDT AG GERMANY (OTCMKTS:BDGXF) had a decrease of 7.25% in short interest. BDGXF’s SI was 6,400 shares in May as released by FINRA. Its down 7.25% from 6,900 shares previously. With 100 avg volume, 64 days are for BERTRANDT AG GERMANY (OTCMKTS:BDGXF)’s short sellers to cover BDGXF’s short positions. The SI to BERTRANDT AG GERMANY’s float is 0.15%. It closed at $108.001854 lastly. It is down 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Trading of Hikma Pharmaceuticals PLC (LON:HIK)‘s shares is going to be interesting today, as Numis decreased the stock to a “Add”. Along the rating downgrade, Numis analysts gave a target price per share of GBX 1560.00 or 13.33% more.

Among 15 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 7 have Buy rating, 2 Sell and 6 Hold. Therefore 47% are positive. Hikma Pharmaceuticals PLC has GBX 3400 highest and GBX 800 lowest target. GBX 1440.07’s average target is 3.62% above currents GBX 1389.702 stock price. Hikma Pharmaceuticals PLC had 179 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 18 by J.P. Morgan. The rating was maintained by Numis Securities with “Buy” on Thursday, November 10. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, September 1. On Tuesday, November 15 the stock rating was upgraded by Morgan Stanley to “Overweight”. On Tuesday, June 27 the stock rating was maintained by JP Morgan with “Neutral”. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, March 15. The stock has “Overweight” rating by JP Morgan on Wednesday, September 14. Numis Securities maintained it with “Buy” rating and GBX 1300 target in Wednesday, December 20 report. Cantor Fitzgerald maintained it with “Buy” rating and GBX 2500 target in Thursday, November 10 report. The rating was maintained by JP Morgan with “Neutral” on Friday, September 29.

Hikma Pharmaceuticals PLC develops, makes, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. The company has market cap of 3.35 billion GBP. It operates through three divisions: Branded, Injectables, and Generic. It currently has negative earnings. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system , gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

The stock decreased 0.74% or GBX 10.298 during the last trading session, reaching GBX 1389.702. About 204,386 shares traded. Hikma Pharmaceuticals PLC (LON:HIK) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.